Genetic stratification of neuroblastoma for treatment tailoring. (September 2011)

• Record Type: Journal Article
• Authors: Jeison, Marta; Yaniv, Isaac; Ash, Shifra
• Is Part Of: Future oncology. Volume 7:Number 9(2011)
• Page Start: 1087
• Page End: 1099
• Publication Date: 2011-09
• Subjects: aCGH -- epigenetic profile -- genetic subtyping -- neuroblastoma -- PAM classifier -- risk stratification -- SNP; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.11.87
• Languages: English
• ISSNs: 1479-6694

Abstract

Neuroblastoma is the most common extracranial tumor of childhood. The clinical behavior is variable, ranging from spontaneous regression to fatal progression despite aggressive therapy. The most highly statistically significant and clinically relevant factors that are currently used for classification include stage, age, histopathologic category, MYCN oncogene status, chromosome 11q status and DNA ploidy. These genetic markers were analyzed separately by classical methods until recently: mainly fluorescence in situ hybridization or loss of heterozygosity. The development of genome-wide techniques such as comparative genomic hybridization, array comparative genomic hybridization and single nucleotide polymorphism allows the analysis of copy number variations through the whole genome in one step. This enabled the investigators to refine different genetic subtypes for the better comprehension of neuroblastoma tumor behavior and reach the conclusion that these data together with a genomic profile based on gene expression should be included in future treatment stratification.